DoW Prostate Cancer, Physician Research Award

The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the FY26 PCRP Overarching Challenges, which include improving overall health, wellness, and survivorship for those impacted by prostate cancer, developing new treatments or improving existing therapies to improve outcomes for patients with lethal prostate cancer, enhancing clinical care for all patients with prostate cancer, and defining the biology of prostate cancer progression to lethal prostate cancer to reduce death. The award requires a mentored research experience, and the application should include a researcher development plan prepared with guidance from the mentor(s). The plan should articulate a strategy for acquiring necessary skills, competence, and expertise to complete the proposed research project and foster the PI’s development as an independent prostate cancer physician-scientist. • The award is open to extramural and intramural U.S. Department of War (DOW) organizations, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities. • The Principal Investigator (PI) must be an early-career physician investigator with clinical duties and/or responsibilities who is either in the last year of an accredited graduate medical education program or within five years of initiating their first faculty appointment. • Applications must include at least one mentor with an established research program in prostate cancer and a commitment to advancing the PI’s career in prostate cancer research. • The proposed research must address one or more of the FY26 PCRP Overarching Challenges and demonstrate in-depth analysis of the research problem presented. • The application should clearly articulate the potential impact of the research, both short-term and long-term, in addressing the FY26 PCRP overarching challenge(s). • High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.